Chronic Rhinosinusitis
Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- No — investigated off-label. The FDA cleared medicinal leeches in 2004 only for venous congestion in microsurgical reconstruction (K040187). Use for chronic sinusitis is supported by one published trial but not FDA-evaluated.
- ¿Qué evidencia existe?
- One randomized trial (Aydin 2017, n=40) reported a 47 percent improvement in the SNOT-22 sinus symptom score at 4 weeks following a single leech session, compared with 14 percent improvement with saline nasal rinses alone. Headache and facial pressure improved more than nasal stuffiness. This is a single, small, single-center trial without long-term follow-up — the evidence is limited and not appropriate for sinusitis with nasal polyps, fungal infection, or any orbital involvement.
- Riesgos principales
- Bleeding and oozing from bite sites on the face for several hours
- Bruising and swelling on the face for 3 to 7 days, which can be cosmetically noticeable
- Itching, redness, and irritation at the bite sites lasting days to weeks
- Small permanent scars on the face (especially the cheek, forehead, or bridge of nose)
- Local skin infection or, rarely, Aeromonas infection from leech gut bacteria
- Allergic reaction to leech saliva (uncommon)
- Risk of leech migration toward the eye if applied too close to the eyelid (requires experienced practitioner)
- Quién no debería considerar esto
- Patients taking blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, or heparin
- Patients with hemophilia or other inherited bleeding disorders
- Patients with severe anemia (hemoglobin under 10 g/dL)
- Patients with a weakened immune system
- Patients with nasal polyps (surgical evaluation is preferred)
- Patients with fungal sinusitis (needs antifungal treatment)
- Patients with active orbital cellulitis or other eye involvement (medical emergency)
- Patients who are particularly concerned about visible facial scarring
- Qué preguntar a su clínico
- Has my sinusitis been properly evaluated by an ENT specialist, including imaging if indicated?
- Do I have nasal polyps, fungal disease, or another structural problem that makes me a poor candidate?
- Have I done standard treatments — saline rinses, intranasal steroids, and antibiotics if bacterial?
- What is the practitioner's experience applying leeches to the face safely without ocular risk?
- What antibiotic plan do you use for Aeromonas prevention?
- How visible will the bruising and scarring be, and how long will they last?
- What is the cost, and is it covered by insurance? (usually not)
- Cuándo buscar atención urgente
- Sudden severe headache, vision changes, eye pain, or swelling around the eye (possible orbital cellulitis — emergency)
- Stiff neck, very high fever, or confusion (possible intracranial spread of infection — emergency)
- Bleeding from a bite site lasting more than 24 hours
- Spreading facial redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Qué NO significa esto
- It does not mean leech therapy is FDA-approved for sinusitis — it is not.
- It does not mean leech therapy cures sinusitis — even in the published trial, the underlying inflammation may return.
- It does not mean leech therapy is better than standard medical care (saline rinses, intranasal steroids, antibiotics when bacterial) or sinus surgery — it is at best an adjunct in carefully selected cases.
- It does not mean facial application is risk-free — bruising can be cosmetically significant, and improper placement near the eye is dangerous.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- ent
- ICD-10
- J32.0, J32.1, J32.2, J32.3, J32.4, J32.8, J32.9
- Safety tier
- low
Evidence Summary
No controlled clinical trial or case series of leech therapy for chronic rhinosinusitis has been published, and PubMed indexes no clinical evidence for this indication. Any proposed benefit (local mucosal decongestion) is hypothetical and mechanistic only. Use is investigational and is not a substitute for established management; it is in particular not appropriate for sinusitis with nasal polyps or a fungal etiology.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Aydın MA et al. (2017), n=40
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Sinusitis with nasal polyposis (surgical referral preferred)
- Fungal sinusitis
- Active orbital cellulitis
Related Conditions
Subjective Tinnitus
Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.
Ménière's Disease (Adjunctive)
Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.
Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; case-report evidence only.
Meniere's Disease (Vestibular Attack Frequency)
Investigational adjunct for vestibular attack frequency reduction in definite Meniere's disease per AAO-HNS 2015 criteria; case-series evidence.